Monoclonal antibody · Agonist of OX40 (TNFRSF4) · developed by Inhibrx Biosciences
Ordastobart is a hexavalent humanized IgG antibody that binds and clusters OX40 receptors on T-lymphocytes, activating them to proliferate and survive. It is studied in solid tumors including non-small cell lung cancer, head and neck cancer, melanoma, gastric cancer, renal cell carcinoma, and urothelial carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06295731 | Phase 2/3 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Active not recruiting | INBX |
| NCT04198766 | Phase 1/2 | Solid Tumor | Recruiting | INBX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Gastric CancerHead and Neck CancerHead and Neck Squamous Cell Carcinoma (HNSCC)MelanomaNon-Small Cell Lung CancerRenal Cell CarcinomaResectable Non-Small-Cell Lung CancerSolid TumorUrothelial Carcinoma
Updated Oct 3, 2026. Something wrong or missing? Report it on the INBX page.
See INBX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INBX catalysts and pipeline →